Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients

• Status: Recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This first-in-human clinical study is a Phase 1a/ 1b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and PK/PD of NTR-441 in healthy subjects and patients with COVID-19 after single ascending IV infusion doses and multiple ascending IV infusion doses.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neutrolis

Criteria

Healthy volunteers:

Inclusion Criteria:

• Male or female, non-smoker, ≥18 and ≤55 years of age, with Body Mass Index (BMI) > 18.5 and < 32.0 kg/m2

• Healthy with no clinically significant findings, determined by medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations) at Screening

• Subject is able to understand and is willing to comply with all study requirements, and willing to follow the instructions of the study staff.

• Subject voluntarily agrees to participate in this study.

Exclusion Criteria:

• Pregnancy, nursing, and/or breastfeeding.

• Study participant has a history of an anaphylactic reaction.

• Subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug.

• Has received any prescription or nonprescription over-the-counter (except occasional use of acetaminophen, paracetamol or ibuprofen) medication, topical medications, vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is longer.

• Subject has a positive urine test for drugs of abuse at the screening visit or admission.

• Regular consumption of alcohol within 6 months prior to Screening or use of illicit substances within 3 months prior to screening.

• Subject has positive test for SARS-CoV-2 infection, human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis C.

• Donation or loss of blood or plasma within 4 weeks prior to initial dosing.

• Subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that will affect the subject's ability to participate in the study.

• Subject has a clinically relevant abnormal ECG; abnormal laboratory values.

• Subject has hypertension.

COVID-19 patients:

Inclusion Criteria:

• Male or female, non-smoker, ≥18 years of age.

• Participant has active laboratory-confirmed SARS-CoV-2 infection.

• Participant must be hospitalized for COVID-19 pneumonia.

• Ability to provide informed consent personally, or by a legally acceptable representative if the participant is unable to do so.

Exclusion Criteria:

• Pregnancy, nursing, and/or breastfeeding.

• History of an anaphylactic reaction.

• In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.

• Severely immune-compromised participants.

• Participant known to test positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis C.

• Any other clinical conditions that in the opinion of the Investigator would make the participants unsuitable for the study.

• Prior treatment with any investigational drug therapy against coronavirus infection within 5 half-lives, prior to enrollment

• Participants who have received an experimental (or, in future, potentially a licensed) immunization or remdesivir against coronavirus remain eligible.

• Participation in another clinical study with the study intervention administered from 30 days or 5 half-lives whichever is longer.

• Anticipated transfer to another hospital which is not a study site during the intervention period.